Top entities: Paragon Therapeutics, Schall Brown & Schwartz LLP, United States — Food and Drug Administration, United States — United States Securities and Exchange Commission, Brian Schall.

What category does this event fall under?

Regulatory — classified as class action.

What is the sentiment of coverage?

Aggregate sentiment score: -30 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This is an active story, last updated Aug 03, 2026. Coverage continues to evolve.

Regulatory class action

Capricor Securities Fraud Class Action

Q: When did this event occur?

First reported Aug 01, 2026; last updated Aug 03, 2026.

Q: What is the market impact?

General. The lawsuit adds regulatory and legal overhang on Capricor, potentially pressuring its stock price and raising uncertainty about the approval prospects of Deramiocel.

Analysis based on 6 articles · First reported Aug 01, 2026 · Last updated Aug 03, 2026

Sentiment

-30

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The lawsuit adds regulatory and legal overhang on Capricor, potentially pressuring its stock price and raising uncertainty about the approval prospects of Deramiocel. The market may react negatively to the allegations of misleading disclosures, affecting investor confidence in the company's clinical and regulatory processes.

Biotechnology Pharmaceuticals

Event Summary

Schall Brown & Schwartz LLP (SBS) announced a securities class action lawsuit against Paragon Therapeutics, Inc. (NASDAQ: CAPR) for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5. The complaint alleges that Capricor made false and misleading statements by changing the statistical analysis plan for its Deramiocel clinical data without FDA agreement before resubmitting its Biologics License Application (BLA), creating a significant risk that the FDA would not approve the BLA due to insufficient evidence of effectiveness. The class period is December 17, 2025 to July 26, 2026, with a lead plaintiff deadline of September 28, 2026. Investors who purchased CAPR shares during this period and suffered losses are encouraged to contact SBS.

Key Actions

100 Schall Brown & Schwartz LLP filed class action Paragon Therapeutics

Entities Involved

priv

Paragon Therapeutics

Capricor is the defendant in the securities fraud class action, facing allegations of misleading investors about its Deramiocel BLA. The lawsuit could lead to financial damages and reputational harm, and may negatively impact its stock price and regulatory outlook.

Importance 100.0 Sentiment -40.0

priv

Schall Brown & Schwartz LLP

SBS is the law firm filing and publicizing the class action, seeking lead plaintiff appointments. The firm benefits from increased visibility and potential fees if the case succeeds.

Importance 80.0 Sentiment 10.0

govactor

United States — Food and Drug Administration

The FDA is central to the allegations, as Capricor allegedly changed its statistical analysis plan without FDA agreement, affecting the BLA review. The FDA's eventual decision on Deramiocel will be pivotal.

Importance 50.0 Sentiment 0.0

govactor

United States — United States Securities and Exchange Commission

The SEC is referenced as the regulator under whose rules the alleged violations occurred, but is not a direct party in the lawsuit.

Importance 30.0 Sentiment 0.0

per

Brian Schall

Brian Schall is a partner at SBS and a contact for investors, playing a role in the litigation but not directly impacted financially.

Importance 20.0 Sentiment 0.0

per

David Schwartz (disambiguation)

David Schwartz (disambiguation) is a partner at SBS and a contact for investors, involved in the case but not directly impacted financially.

Importance 20.0 Sentiment 0.0

per

Andrew Brown

Andrew Brown is a partner at SBS, contributing to the firm's litigation efforts but not directly impacted financially.

Importance 20.0 Sentiment 0.0

Relationships

Paragon Therapeutics related ↔ United States — Food and Drug Administration

Schall Brown & Schwartz LLP related ↔ United States — United States Securities and Exchange Commission

Schall Brown & Schwartz LLP related ↔ Brian Schall

Schall Brown & Schwartz LLP related ↔ David Schwartz (disambiguation)

Schall Brown & Schwartz LLP related ↔ Andrew Brown

United States — Food and Drug Administration related ↔ United States — United States Securities and Exchange Commission

United States — Food and Drug Administration related ↔ Brian Schall

United States — United States Securities and Exchange Commission related ↔ Brian Schall

United States — United States Securities and Exchange Commission related ↔ David Schwartz (disambiguation)

United States — United States Securities and Exchange Commission related ↔ Andrew Brown

Brian Schall founding partner ↔ David Schwartz (disambiguation) Brian Schall is a founding partner of Schall, Brown & Schwartz LLP, a national shareholder rights litigation firm, along

Brian Schall related ↔ Andrew Brown

David Schwartz (disambiguation) related ↔ Andrew Brown

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard